Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL MarketWatch (press release) According to the amended protocol all patients recruited in the study which investigates ofatumumab plus chemotherapy versus rituximab plus chemotherapy in relapsed or refractory DLBCL, will receive the same chemotherapy regimen (DHAP). |
